Maxim Group acted as sole book-running manager on Contrafect Corporation’s $36.0 million initial public offering

YONKERS, NY — (Marketwired) — 08/04/14 — ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that on August 1, 2014 it closed its initial public offering of 6,000,000 units at a price of$6.00 per unit. The units are listed on the Nasdaq Capital Market and trade under the symbol “CFRXU.”ContraFect received approximately $32.7 million of proceeds from the offering, net of underwriting discounts and commissions and other estimated expenses.

This entry was posted in Uncategorized. Bookmark the permalink.